Condition
Diabetes Mellitus, Type 2
Locations
Argentina, Brazil, Israel, Malaysia, Thailand, United States
Start date
04/08/2026
Identifiers
Trial ID NN9388-7988,
NCT number NCT07282613,
Eudract number Not Available
NCT number NCT07282613,
Eudract number Not Available
Summary
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.
Trial Overview:
Treatment
DRUG: CagriSema (Cagrilintide B and Semaglutide I)
DRUG: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Study type
INTERVENTIONAL
Trial duration
Aug 04 2026 - Mar 30 2030
Participants
80
Phase
III
Are you eligible?
Gender
Male and female
Age
10 to 18 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.